Nuijen B - Search Results

1

Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.

van der Schoot SC, Nuijen B, Huitema AD, Beijnen JH. van der Schoot SC, et al. Among authors: nuijen b. Pharm Res. 2007 Mar;24(3):605-12. doi: 10.1007/s11095-006-9179-y. Pharm Res. 2007. PMID: 17245647 Free PMC article.

2

Alternative formulations of paclitaxel.

Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Terwogt JM, et al. Among authors: nuijen b. Cancer Treat Rev. 1997 Mar;23(2):87-95. doi: 10.1016/s0305-7372(97)90022-0. Cancer Treat Rev. 1997. PMID: 9225960 Review.

3

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

Nuijen B, Bouma M, Henrar RE, Manada C, Bult A, Beijnen JH. Nuijen B, et al. Anticancer Drugs. 1999 Nov;10(10):879-87. doi: 10.1097/00001813-199911000-00003. Anticancer Drugs. 1999. PMID: 10630355

4

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

Nuijen B, Bouma M, Henrar RE, Brauns U, Bette P, Bult A, Beijnen JH. Nuijen B, et al. Int J Pharm. 2000 Jan 25;194(2):261-7. doi: 10.1016/s0378-5173(99)00389-0. Int J Pharm. 2000. PMID: 10692650

5

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

Nuijen B, Bouma M, Henrar RE, Floriano P, Jimeno JM, Talsma H, Kettenes-van den Bosch JJ, Heck AJ, Bult A, Beijnen JH. Nuijen B, et al. PDA J Pharm Sci Technol. 2000 May-Jun;54(3):193-208. PDA J Pharm Sci Technol. 2000. PMID: 10927911

6

Pharmaceutical development of anticancer agents derived from marine sources.

Nuijen B, Bouma M, Manada C, Jimeno JM, Schellens JH, Bult A, Beijnen JH. Nuijen B, et al. Anticancer Drugs. 2000 Nov;11(10):793-811. doi: 10.1097/00001813-200011000-00003. Anticancer Drugs. 2000. PMID: 11142687 Review.

7

Progress in the development of alternative pharmaceutical formulations of taxanes.

Nuijen B, Bouma M, Schellens JH, Beijnen JH. Nuijen B, et al. Invest New Drugs. 2001 May;19(2):143-53. doi: 10.1023/a:1010682916808. Invest New Drugs. 2001. PMID: 11392448 Review.

8

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.

Nuijen B, Bouma M, Manada C, Jimeno JM, Bult A, Beijnen JH. Nuijen B, et al. PDA J Pharm Sci Technol. 2001 Jul-Aug;55(4):223-9. PDA J Pharm Sci Technol. 2001. PMID: 11505554

9

Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.

Nuijen B, Bouma M, Manada C, Jimeno JM, Lazaro LL, Bult A, Beijnen JH. Nuijen B, et al. Invest New Drugs. 2001;19(4):273-81. doi: 10.1023/a:1010641207791. Invest New Drugs. 2001. PMID: 11561686

10

Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.

Nuijen B, Bouma M, Talsma H, Manada C, Jimeno JM, Lopez-Lazaro L, Bult A, Beijnen JH. Nuijen B, et al. Drug Dev Ind Pharm. 2001 Sep;27(8):767-80. doi: 10.1081/ddc-100107240. Drug Dev Ind Pharm. 2001. PMID: 11699828

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters